Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?

SIMPLE SUMMARY: Lung cancer is one of the most common human cancers and the leading cause of cancer-related mortality worldwide. The advent of immunotherapy for the treatment of non-small cell lung cancer has significantly improved progression-free survival, overall survival, and the patient’s quali...

Descripción completa

Detalles Bibliográficos
Autores principales: Putzu, Carlo, Canova, Stefania, Paliogiannis, Panagiotis, Lobrano, Renato, Sala, Luca, Cortinovis, Diego Luigi, Colonese, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913378/
https://www.ncbi.nlm.nih.gov/pubmed/36765647
http://dx.doi.org/10.3390/cancers15030689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913378/
https://www.ncbi.nlm.nih.gov/pubmed/36765647
http://dx.doi.org/10.3390/cancers15030689

Ejemplares similares